|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
ΔSUVmax*ΔSLD may be a promising parameter to interpret iPET/CT images, reflecting both the changes in tumor size and metabolic activity.
|
31293092 |
2019 |
|
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
With regard to the antitumor activity of Co-SLD, inhibited cell growth and migration capability were outstandingly observed in oral squamous cell carcinoma treated with 10 and 20 μM Co-SLD, which could be mainly attributed to the Co-SLD-elicited mitochondrial damage as marked by the depression of mitochondrial membrane potential, ROS accumulation and ATP depletion.
|
31062618 |
2019 |
|
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
With regard to the antitumor activity of Co-SLD, inhibited cell growth and migration capability were outstandingly observed in oral squamous cell carcinoma treated with 10 and 20 μM Co-SLD, which could be mainly attributed to the Co-SLD-elicited mitochondrial damage as marked by the depression of mitochondrial membrane potential, ROS accumulation and ATP depletion.
|
31062618 |
2019 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
With regard to the antitumor activity of Co-SLD, inhibited cell growth and migration capability were outstandingly observed in oral squamous cell carcinoma treated with 10 and 20 μM Co-SLD, which could be mainly attributed to the Co-SLD-elicited mitochondrial damage as marked by the depression of mitochondrial membrane potential, ROS accumulation and ATP depletion.
|
31062618 |
2019 |
|
Liver Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ<sup>2</sup>=6.295, P=0.012), ALT (χ<sup>2</sup>=18.803, P=0.000), AST (χ<sup>2</sup>=33.421, P=0.000), tumor nodule number (χ<sup>2</sup>=6.777, P=0.009), cirrhosis (χ<sup>2</sup>=43.458, P=0.000), and tumor size (χ<sup>2</sup>=6.042, P=0.014) in the Chi-square test.
|
31495535 |
2019 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ<sup>2</sup>=6.295, P=0.012), ALT (χ<sup>2</sup>=18.803, P=0.000), AST (χ<sup>2</sup>=33.421, P=0.000), tumor nodule number (χ<sup>2</sup>=6.777, P=0.009), cirrhosis (χ<sup>2</sup>=43.458, P=0.000), and tumor size (χ<sup>2</sup>=6.042, P=0.014) in the Chi-square test.
|
31495535 |
2019 |
|
Nodule
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ<sup>2</sup>=6.295, P=0.012), ALT (χ<sup>2</sup>=18.803, P=0.000), AST (χ<sup>2</sup>=33.421, P=0.000), tumor nodule number (χ<sup>2</sup>=6.777, P=0.009), cirrhosis (χ<sup>2</sup>=43.458, P=0.000), and tumor size (χ<sup>2</sup>=6.042, P=0.014) in the Chi-square test.
|
31495535 |
2019 |
|
Neoplasms
|
0.090 |
Biomarker
|
group |
BEFREE |
When samples were grouped according to the serum level of AKR1B10 (≥232.7pg/ml), serum AKR1B10 positively correlated to serum AFP (χ<sup>2</sup>=6.295, P=0.012), ALT (χ<sup>2</sup>=18.803, P=0.000), AST (χ<sup>2</sup>=33.421, P=0.000), tumor nodule number (χ<sup>2</sup>=6.777, P=0.009), cirrhosis (χ<sup>2</sup>=43.458, P=0.000), and tumor size (χ<sup>2</sup>=6.042, P=0.014) in the Chi-square test.
|
31495535 |
2019 |
|
Hemorrhagic Fever, Crimean
|
0.010 |
Biomarker
|
disease |
BEFREE |
We suggest that AST and INR may be important biomarkers for determining the risk of severity and death as a result of infection with Crimean-Congo hemorrhagic fever virus (CCHFV).
|
25815864 |
2015 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.080 |
Biomarker
|
disease |
BEFREE |
We studied alanine and aspartate aminotransferase (ALT and AST) in subjects randomized to placebo who completed assessments over 36 mo in a cardiovascular outcome trial [the Stabilisation of Atherosclerotic Plaque by Initiation of Darapladib Therapy ("STABILITY") trial; n = 4,264; mean age: 64.2 yr] or over 12 mo in three trials that enrolled only subjects with type 2 diabetes (T2D) [the DIA trials; n = 308; mean age: 62.4 yr] to investigate time-dependent relationships and the factors that might affect ALT and AST, including body mass index (BMI), T2D, and renal function.
|
30495974 |
2019 |
|
Severe Dengue
|
0.030 |
Biomarker
|
disease |
BEFREE |
We sought to investigate the differences in monocyte immune responses to the dengue virus (DENV) in those who previously had either severe disease (past SD) or non-severe dengue (past NSD) following a secondary dengue infection.
|
31288040 |
2019 |
|
Diabetes
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively studied SF and post-screening age; sex; body mass index; transferrin saturation (TS); ALT; AST; GGT; elevated C-reactive protein; ß-thalassemia; neutrophils; lymphocytes; monocytes; platelets; metacarpophalangeal joint hypertrophy; hepatomegaly; splenomegaly; diabetes; HFE H63D positivity; iron/alcohol intakes; and blood/erythrocyte transfusion units.
|
28809726 |
2018 |
|
Diabetes Mellitus
|
0.050 |
GeneticVariation
|
group |
BEFREE |
We retrospectively studied SF and post-screening age; sex; body mass index; transferrin saturation (TS); ALT; AST; GGT; elevated C-reactive protein; ß-thalassemia; neutrophils; lymphocytes; monocytes; platelets; metacarpophalangeal joint hypertrophy; hepatomegaly; splenomegaly; diabetes; HFE H63D positivity; iron/alcohol intakes; and blood/erythrocyte transfusion units.
|
28809726 |
2018 |
|
Hepatic necrosis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
We report that hepatocyte-specific deletion of Brg1 attenuated APAP induced liver injury in mice as evidenced by reduced plasma ALT and AST levels, decreased liver necrosis, amelioration of GSH depletion, and prolonged survival.
|
30293568 |
2018 |
|
Dermatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report on the case of two siblings affected by recurrent attacks of fever, oral aphthous stomatitis, abdominal pain, arthritis, undefined dermatitis at the hands, associated with increased AST, ALT, C-reactive protein, erythrocyte sedimentation rate, serum amyloid A, leucocytosis with neutrophilia.Infectious diseases were excluded.
|
31443670 |
2019 |
|
Kidney Failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
We propose that AST-120 reduces IS concentrations in the blood that induces ROS production in endothelial cells, thereby inhibiting the subsequent occurrence of oxidative stress in the systemic circulation in renal failure.
|
17387602 |
2007 |
|
Non-alcoholic Fatty Liver Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed a systematic review with meta-analysis evaluating if NAFLD fibrosis score (NFS), AST to platelet ratio index (APRI), and Fibrosis-4 (FIB-4) score may also predict mortality.
|
30111756 |
2018 |
|
Icterus
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We found that in NP-C patients AST was usually mildly elevated and ALT was in a normal range when jaundice was not present.
|
24915861 |
2014 |
|
Infantile Sialic Acid Storage Disease
|
0.790 |
GeneticVariation
|
disease |
BEFREE |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Infantile Sialic Acid Storage Disease
|
0.790 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Infantile Sialic Acid Storage Disease
|
0.790 |
GeneticVariation
|
disease |
CLINVAR |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Infantile Sialic Acid Storage Disease
|
0.790 |
GeneticVariation
|
disease |
UNIPROT |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Sialic Acid Storage Disease, Finnish Type (disorder)
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Sialic Acid Storage Disease, Finnish Type (disorder)
|
0.800 |
GeneticVariation
|
disease |
CLINVAR |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |
|
Sialic Acid Storage Disease, Finnish Type (disorder)
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We found a homozygous SLC17A5 mutation (R39C) in five Finnish patients with Salla disease and six different SLC17A5 mutations in six ISSD patients of different ethnic origins.
|
10581036 |
1999 |